^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | tenalisib (RP6530) (PI3K inhibitor, PI3Kδ inhibitor, PI3Kγ inhibitor, SIK3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
An Open Label, Phase 2 Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a PI3K d/? and SIK3 Inhibitor, in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Published date:
11/04/2020
Excerpt:
High risk patients included 15% del 17p, 10% del 11q, 5% ZAP and 5% TP53 mutations….In all 21 evaluable pts with a median follow-up of 4.9 months, 7 patients showed partial response (33%) while the remaining 14 patients showed stable disease (67%)….Tenalisib showed promising single agent anti-tumor activity in patients with CLL with a favourable safety profile.
